ANIP Q3 Deep Dive: Rare Disease Momentum and Generics Expansion Drive Upgraded Outlook

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations , with sales up 53.6% year on year to $227.8 million. The company’s full-year revenue guidance of $863.5 million at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.04 per share was 15.2% above analysts’ consensus estimates. Is now the time to buy ANIP? Find out in our full research report (it’s free for active Edge members). ANI Pharmaceut ...